By Katherine Hamilton
Omnicell shares fell after the company lowered its guidance due to expected costs and uncertainty from tariffs.
The stock slid 15% to $26.01 on Tuesday morning, at one point touching a 52-week low of $22.66. Shares have lost roughly 43% of their value this year.
The healthcare-technology company, which automates medication management for hospitals and pharmacies, on Tuesday reduced its full-year guidance to account for higher supply-chain costs from tariffs.
Omnicell is now expecting $1.00 to $1.65 in adjusted earnings per share for all of 2025, down from prior guidance of $1.65 to $1.85. Revenue guidance was unchanged.
Chief Executive Randall Lipps said the company is implementing strategies to mitigate potential tariff-related costs, but that uncertainty about those impacts compelled management to lower guidance.
In the first quarter, Omnicell narrowed its loss to $7 million, or 15 cents a share, from its prior-year loss of $15.7 million, or 34 cents a share. Adjusted earnings were 26 cents a share, ahead of the 20 cents a share forecast by Wall Street.
Revenue in the first quarter rose 10% to $269.7 million, ahead of the $259.9 million expected by analysts, according to FactSet.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 06, 2025 10:25 ET (14:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。